Company profile: Rebiotix
1.1 - Company Overview
Company description
- Provider of microbiome-based therapeutics targeting GI diseases, including FDA-approved REBYOTA for prevention of recurrence of Clostridioides difficile infection in adults; RBX2660, a live biotherapeutic in development for recurrent C. difficile; RBX7455, a non-frozen capsule in feasibility studies; and a Stool Donor Program supporting development of microbiome-based therapeutics.
Products and services
- RBX2660: A development-stage live biotherapeutic product candidate engineered for the treatment of recurrent Clostridioides difficile infection, utilizing human microbiome therapeutics for gastrointestinal disease
- RBX7455: A non-frozen capsule formulation in feasibility studies for the treatment of recurrent Clostridioides difficile infection, delivering microbiome-based therapeutics
- REBYOTA: An FDA-approved live biotherapeutic product preventing recurrence of Clostridioides difficile infection in adults, employing human microbiome therapeutics for gastrointestinal disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rebiotix
Alphyn Biologics
HQ: United States
Website
- Description: Provider of proprietary drug therapies for skin diseases, including Zabalafin hydrogel (AB-101a), a steroid-free topical for atopic dermatitis targeting immune and bacterial components; the Zabalafin (AB-101) multi-bioactive platform; and AB-101b in development for Epidermolysis Bullosa to address inflammation, itch, pain, and skin infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alphyn Biologics company profile →
Protez Pharmaceuticals
HQ: United States
Website
- Description: Provider of differentiated intravenous and oral small molecule antibiotics for difficult-to-treat hospital-based infections, addressing bacterial resistant and chronic or recurrent infections; discovers, develops, and commercializes antibiotic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protez Pharmaceuticals company profile →
T2 Biosystems
HQ: United States
Website
- Description: Provider of rapid, accurate infectious disease diagnostics, including the T2Dx Instrument, a fully automated system running tests directly from whole blood, the FDA-cleared T2Bacteria Panel for identifying sepsis-causing bacteria without blood culture, and T2Candida for detecting invasive candidiasis from whole blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T2 Biosystems company profile →
Helix BioMedix
HQ: United States
Website
- Description: Provider of skin health consumer products and bioactive peptide solutions for dermatological and personal care, including a proprietary peptide library with antimicrobial, anti-inflammatory and wound healing properties; SmartPeptides to enhance skin appearance; Oligopeptide-10 for acne; Palmitoyl Hexapeptide-14 and Hexapeptide-21 to stimulate collagen; and HB4208, a preclinical DNA Damage Response enzyme for Xeroderma Pigmentosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helix BioMedix company profile →
Biotest Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical and biotherapeutic products utilized in immunology, with innovation in haematology, clinical immunology and intensive care medicine, incorporating innovative technologies and a sharp focus on safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotest Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rebiotix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rebiotix
2.2 - Growth funds investing in similar companies to Rebiotix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rebiotix
4.2 - Public trading comparable groups for Rebiotix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →